Ishockey-VM 2023: Var med och heja fram Tre Kronor i ishockey-VM 2023 i Finland! Biljetter till enskilda matcher finns att köpa nu
Finland och Lettland delar på arrangörskapet för ishockey-VM 12–28 maj 2023. Grupp A spelas i Tammerfors, Finland, och grupp B i Riga, Lettland.
Sverige spelar i grupp A i Tammerfors tillsammans med Danmark, Finland, Frankrike, Tyskland, Ungern, USA och Österrike. Kvartsfinalerna spelas i både Tammerfors och Riga, men spelplatsen beror på hur det går i gruppspelet. Semifinalerna och finalen går i Tammerfors.
Biljetter till enskilda matcher finns att köpa nu och det finns fortfarande platser kvar på alla matcher och i samtliga priskategorier, men det gäller att skynda dig om du inte vill gå miste om chansen att få se landslaget i aktion.
Tre Kronor börjar mot Tyskland
Sverige går in i turneringen mot Tyskland kl. 20.20 fredagen den 12 maj. Biljetterna för den här matchen kostar från 39 euro för vuxen och 13 euro för barn.
Den 15 maj kl. 20.20 är det nedsläpp för Tre Kronor mot regerande världsmästarna Finland. Biljetterna kostar från 110 euro för vuxna och 54 euro för barn.
Priserna för enskilda matchbiljetter är exklusive avgifter från biljettbokningsbolag.
Sverige kan peka på fantastiska framgångar i ishockey-VM genom åren med totalt elva VM-guld, där det senaste erövrades i VM 2018.
Var med och heja fram Sverige på plats och smaka på spänningen när världens bästa möts i ishockey.
Sveriges matcher i grupp A (Tammerfors, Finland)
12 maj: Sverige–Tyskland
14 maj: Sverige–Österrike
15 maj: Finland–Sverige
18 maj: Ungern–Sverige
20 maj: Sverige–Frankrike
22 maj: Danmark–Sverige
23 maj: Sverige–USA
Facebook: @2023iihfwm
Twitter: @2023iihfwm
Instagram: @2023iihfwm
IIHF ishockey-VM 2023 https://www.iihf.com/en/events/2023/wm
Spelschema https://www.iihf.com/en/events/2023/wm/schedule
Biljetter https://www.iihf.com/en/events/2023/wm/static/37881/tickets_world_championship
Visit Tampere https://visittampere.fi/en/
Detta meddelandes ursprungliga källspråkstext är den officiella versionen. Översättningar tillhandahålls endast som ett stöd och skall jämföras med källspråkstexten, vilken är den enda versionen av texten som har rättslig verkan.
För att se det här innehållet från cts.businesswire.com måste du ge ditt medgivande sidans topp.
Se källversionen på businesswire.com: https://www.businesswire.com/news/home/20230126005758/sv/
Contact information
Finhockey
Generalsekreterare, Heikki Hietanen
+358-50-373 0303
heikki.hietanen@finhockey.fi
Marknadsförings- och kommunikationschef,
Henna Malmberg, +358-40-573 7572
henna.malmbeg@finhockey.fi
Om
Följ Business Wire
Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.
Senaste pressmeddelandena från Business Wire
Making Science Unveils ‘AWAKE’: The AI Venture Studio Industrialising Startup Creation and AI-First Innovative Solutions23.12.2025 20:51:00 CET | Press Release
Making Science, the global digital acceleration consultancy, today announced the launch of AWAKE Venture Studio. This "AI-first" model represents a new era in systematic innovation, designed to identify, prototype, and scale both internal proprietary solutions and independent AI-native startups with global reach. The launch of AWAKE is motivated by the significant efficiency gains of orders of magnitude that Making Science has already achieved through the internal integration of AI. By applying these methods, the firm has achieved a 2x acceleration in tech feature development reducing time in the deployment of AI Agents. This model has already proven its commercial and innovative power through the acceleration of startups like ad-machina, which has multiplied its value by 10 since joining the Making Science ecosystem. These proven benchmarks serve as the technical foundation for AWAKE’s two interconnected engines, which formalise this efficiency into a repeatable manufacturing process
FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia23.12.2025 18:07:00 CET | Press Release
The Cataltheia Group and its U.S. subsidiary, Bruno Vision Care LLC, a leader in eye health innovation, today announced that the U.S. Food and Drug Administration (FDA) has cleared the first and only Daily Disposable Soft (Hydrophilic) Contact Lens for Presbyopia utilizing patented Extended Depth of Focus (EDOF) optical design technology, enabling commercial distribution in the United States. Deseyne® delivers smooth, continuous focus across near, intermediate, and distance vision, providing clear, natural vision without compromise. This performance is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner. The result is a clear clinical advantage over the only other available contact lens option for presbyopia, multifocal lenses, which rely on multiple optical zones and often require prolonged visual and cognitive adaptation. “We are proud to offer the first contact lens solution for the world’s aging population th
Aramco Awards SLB Long-Term Contract to Support Kingdom’s Unconventional Gas Production Growth23.12.2025 14:58:00 CET | Press Release
Global technology company SLB (NYSE: SLB) has been awarded a five-year contract by Aramco to provide stimulation services for its unconventional gas fields. This award is part of a broader multi-billion contract, supporting one of the largest unconventional gas development programs globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251223074948/en/ The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources. The contract encompasses advanced stimulation, well intervention, frac automation, and digital solutions, which are important to unlocking the potential of Saudi Arabia’s unconventional gas resources — a cornerstone of the Kingdom’s strategy to diversify its energy portfolio and support the global energy transition. “This agreement is an important step forward in Aramco’s effor
Tabelog, Japan's Largest (*1) Restaurant Search and Reservation Service, Launches Multilingual App for International Visitors23.12.2025 14:00:00 CET | Press Release
Tabelog (https://tabelog.com/en/), Japan's largest restaurant search and reservation service operated by Kakaku.com, Inc., launched its multilingual smartphone application (iOS/Android) for international travelers on Monday, November 17, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221963753/en/ The Tabelog Multilingual App for International Travelers — Japan's Largest Restaurant Search and Reservation Service With approximately 100 million monthly users(*3), Tabelog is Japan's premier service widely used by Japanese locals for daily restaurant discovery. Its database is unrivaled domestically, featuring information on approximately 890,000 establishments nationwide and over 85 million reviews and photos(*4). Unlike global map services or travel sites, Tabelog is built on "authentic ratings and reviews from local Japanese users," enabling travelers to discover truly exceptional restaurants beloved by locals — not
BeOne Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference23.12.2025 12:01:00 CET | Press Release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026, with a presentation at 7:30 am PST. Live webcasts of these events can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com, https://hkexir.beonemedicines.com, https://sseir.beonemedicines.com. Archived replays will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company based in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.
Besök vårt pressrum
